| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1020458276 |
| P356 | DOI | 10.1186/CC3781 |
| P932 | PMC publication ID | 3226119 |
| P698 | PubMed publication ID | 16221315 |
| P5875 | ResearchGate publication ID | 7545505 |
| P2093 | author name string | Myung S Park | |
| Anthony E Pusateri | |||
| P2860 | cites work | Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial | Q78840677 |
| The use of recombinant factor VIIa in severe postpartum hemorrhage | Q80344979 | ||
| Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model | Q80347296 | ||
| Effect of recombinant FVIIa in hypothermic, coagulopathic pigs with liver injuries | Q81050421 | ||
| Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine | Q81402653 | ||
| Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque | Q24339425 | ||
| The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability | Q28165369 | ||
| A cell-based model of hemostasis | Q28204461 | ||
| Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation | Q28254159 | ||
| The tissue factor pathway: how it has become a "prima ballerina" | Q28631248 | ||
| The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. | Q30448825 | ||
| Recombinant activated factor VII used in a man with refractory bleeding from a stab wound injuring the liver and kidney | Q33204161 | ||
| Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions | Q33331699 | ||
| Transfusion medicine service policies for recombinant factor VIIa administration | Q33362187 | ||
| Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count | Q33365901 | ||
| Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. | Q33504352 | ||
| Biochemistry and physiology of blood coagulation. | Q33799936 | ||
| The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders | Q34090256 | ||
| WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | Q34257361 | ||
| Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation | Q34303816 | ||
| The use of recombinant factor VIIa in the treatment of bleeding disorders. | Q34343186 | ||
| Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development | Q34362575 | ||
| The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. | Q34458071 | ||
| Disseminated intravascular coagulation in trauma patients | Q34461301 | ||
| Factor XI activation in a revised model of blood coagulation | Q34500136 | ||
| Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy | Q34522223 | ||
| Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation | Q35047906 | ||
| Treating coagulopathy in trauma patients | Q35185225 | ||
| Monitoring coagulation and the clinical effects of recombinant factor VIIa | Q35661480 | ||
| Views on methods for monitoring recombinant factor VIIa in inhibitor patients | Q35661495 | ||
| Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation | Q62107359 | ||
| Activation of human factor V by factor Xa and thrombin | Q68747564 | ||
| Tissue factor pathway inhibitor | Q70943593 | ||
| Transmission of a procoagulant signal from tissue factor-bearing cell to platelets | Q71612091 | ||
| A model for the tissue factor pathway to thrombin. I. An empirical study | Q72181568 | ||
| Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis | Q73114039 | ||
| Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device | Q73142092 | ||
| The use of recombinant factor VIIa in children with inherited platelet function disorders | Q73320925 | ||
| Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems | Q73497164 | ||
| Mechanism of action of recombinant factor VIIa | Q73690484 | ||
| Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases | Q73848430 | ||
| Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study | Q73933603 | ||
| An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII | Q74268022 | ||
| Recombinant factor VIIa treatment of bleeding associated with acute renal failure | Q74346045 | ||
| The use of recombinant activated factor VII to control bleeding in a preterm infant undergoing exploratory laparotomy | Q74398520 | ||
| Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy | Q74428289 | ||
| Synthetic factor VIIa to treat dilutional coagulopathy during posterior spinal fusion in two children | Q74593898 | ||
| Successful use of recombinant activated factor VII (Novoseven) in controlling severe intra-abdominal bleeding after liver needle biopsy | Q77670272 | ||
| The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. | Q77800200 | ||
| Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor | Q77920757 | ||
| Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis | Q35661530 | ||
| Thromboelastography and recombinant factor VIIa-hemophilia and beyond | Q35661536 | ||
| Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors | Q35771690 | ||
| Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding | Q35839531 | ||
| Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential | Q35879063 | ||
| Treating traumatic bleeding in a combat setting: possible role of recombinant activated factor VII. | Q36009737 | ||
| Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors | Q36990492 | ||
| Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. | Q42138675 | ||
| Modulation of endothelial cell hemostatic properties by tumor necrosis factor | Q42151543 | ||
| Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries | Q43575604 | ||
| Extracellular pH affects platelet aggregation associated with modulation of store-operated Ca(2+) entry | Q43818632 | ||
| Capacitative calcium influx and intracellular pH cross-talk in human platelets | Q44353415 | ||
| Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia | Q44359025 | ||
| Recombinant activated factor VII for adjunctive hemorrhage control in trauma | Q44472174 | ||
| Factor VIIa for correction of traumatic coagulopathy | Q45130198 | ||
| Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury | Q45857141 | ||
| Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia | Q45857666 | ||
| Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. | Q45858062 | ||
| The Effect of Recombinant Factor VIIa on Noncoagulopathic Pigs with Grade V Liver Injuries | Q45862242 | ||
| Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients | Q45863098 | ||
| How factor VIIa works in hemophilia | Q45863820 | ||
| The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. | Q45863825 | ||
| Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation | Q45863892 | ||
| Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa | Q45871588 | ||
| A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment | Q45873675 | ||
| Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. | Q45876353 | ||
| Recombinant factor VIIa: a general hemostatic agent? Yes. | Q45878443 | ||
| Recombinant factor VIIa: a general hemostatic agent? Not yet. | Q45878448 | ||
| Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. | Q45878840 | ||
| Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. | Q45882175 | ||
| Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force | Q45882922 | ||
| Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa | Q45883227 | ||
| Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors | Q45884134 | ||
| Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor | Q45884478 | ||
| Platelet activity of high-dose factor VIIa is independent of tissue factor | Q45884609 | ||
| The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries | Q45888438 | ||
| Injury induces increased monocyte expression of tissue factor: factors associated with head injury attenuate the injury-related monocyte expression of tissue factor | Q46512576 | ||
| Recombinant activated factor VII for the treatment of life-threatening haemorrhage | Q47388493 | ||
| Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. | Q50758503 | ||
| Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. | Q50775941 | ||
| A model for the tissue factor pathway to thrombin. II. A mathematical simulation. | Q52371258 | ||
| Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. | Q53304056 | ||
| Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). | Q53386785 | ||
| Treatment of traumatic bleeding with recombinant factor VIIa. | Q55033461 | ||
| Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. | Q55067704 | ||
| The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients | Q61405306 | ||
| P921 | main subject | blood coagulation | Q179217 |
| injury | Q193078 | ||
| zymogen | Q245759 | ||
| protein precursor | Q258658 | ||
| blood proteins | Q425056 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | S15-24 | |
| P577 | publication date | 2005-10-07 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma | |
| P478 | volume | 9 Suppl 5 |
| Q33282917 | Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding |
| Q37117872 | Hemostatic therapy for the treatment of intracranial hemorrhage |
| Q38267207 | NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia |
| Q33375346 | Pharmacology and clinical use of recombinant activated factor seven in neurosciences |
| Q33372308 | Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma |
| Q34005911 | Recombinant factor VII is associated with worse survival in complex cardiac surgical patients |
| Q36152281 | Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time |
Search more.